Here's something you might be interested in.
Ask a Hipster — Advice you didn't know you needed
Big Screen — Movie commentary
Blurt — Music's inside track
Booze News — San Diego spirits
Classical Music — Immortal beauty
Classifieds — Free and easy
Cover Stories — Front-page features
Drinks All Around — Bartenders' drink recipes
Excerpts — Literary and spiritual excerpts
Feast! — Food & drink reviews
Feature Stories — Local news & stories
Fishing Report — What’s getting hooked from ship and shore
From the Archives — Spotlight on the past
Golden Dreams — Talk of the town
The Gonzo Report — Making the musical scene, or at least reporting from it
Letters — Our inbox
Movies@Home — Local movie buffs share favorites
Movie Reviews — Our critics' picks and pans
Musician Interviews — Up close with local artists
Neighborhood News from Stringers — Hyperlocal news
News Ticker — News & politics
Obermeyer — San Diego politics illustrated
Outdoors — Weekly changes in flora and fauna
Overheard in San Diego — Eavesdropping illustrated
Poetry — The old and the new
Reader Travel — Travel section built by travelers
Reading — The hunt for intellectuals
Roam-O-Rama — SoCal's best hiking/biking trails
San Diego Beer — Inside San Diego suds
SD on the QT — Almost factual news
Sheep and Goats — Places of worship
Special Issues — The best of
Street Style — San Diego streets have style
Surf Diego — Real stories from those braving the waves
Theater — On stage in San Diego this week
Tin Fork — Silver spoon alternative
Under the Radar — Matt Potter's undercover work
Unforgettable — Long-ago San Diego
Unreal Estate — San Diego's priciest pads
Your Week — Daily event picks
Biotechs belted
Hillary and Bernie holler at price jack-up of pill that jumped from $13.50 to $750
Biotech stocks got walloped today (September 21) after a startup pharmaceutical company named Turing Pharmaceuticals boosted the price of a drug overnight from $13.50 to $750 a tablet. It's a 62-year-old drug for treating life-threatening parasitic infections that affects some AIDS and cancer patients.
Martin Shkreli
Turing is headed by Martin Shkreli, a young, former hedge-fund popinjay who defended the price leap and said he has no plans to rescind it. Presidential candidate Hillary Clinton denounced the move as price-gouging. Candidate Bernie Sanders also chimed in against it.
Biotech stocks got hit hard. They had been on a long run-up and this spring began returning to earth.
Among San Diego biotechs, Halozyme Therapeutics dropped 4.96 percent to $18.22; Illumina dropped 4.16 percent to $200.19; ISIS Pharmaceuticals plunged 7.99 percent to $50.20; La Jolla Pharmaceutical plummeted 8.42 percent to $38.18; Ligand Pharmaceuticals dropped 3.96 percent to $97.90; and Neurocrine Biosciences got machine-gunned 8.6 percent to $50.18.
Here's something you might be interested in.
Biotechs belted
Hillary and Bernie holler at price jack-up of pill that jumped from $13.50 to $750
Biotechs belted
Hillary and Bernie holler at price jack-up of pill that jumped from $13.50 to $750
Biotech stocks got walloped today (September 21) after a startup pharmaceutical company named Turing Pharmaceuticals boosted the price of a drug overnight from $13.50 to $750 a tablet. It's a 62-year-old drug for treating life-threatening parasitic infections that affects some AIDS and cancer patients.
Martin Shkreli
Turing is headed by Martin Shkreli, a young, former hedge-fund popinjay who defended the price leap and said he has no plans to rescind it. Presidential candidate Hillary Clinton denounced the move as price-gouging. Candidate Bernie Sanders also chimed in against it.
Biotech stocks got hit hard. They had been on a long run-up and this spring began returning to earth.
Among San Diego biotechs, Halozyme Therapeutics dropped 4.96 percent to $18.22; Illumina dropped 4.16 percent to $200.19; ISIS Pharmaceuticals plunged 7.99 percent to $50.20; La Jolla Pharmaceutical plummeted 8.42 percent to $38.18; Ligand Pharmaceuticals dropped 3.96 percent to $97.90; and Neurocrine Biosciences got machine-gunned 8.6 percent to $50.18.
Comments